To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. For more information, please visit www.immunomix.com. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. Melissa Kemp Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. immunomic therapeutics crunchbase - xarxacatala.cat Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. CONTACT US. ITI-1000 GBM - Cell Therapy. Careers - Immunomic Therapeutics Nature. Stock ticker symbol (e.g. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. 1K followers 500+ connections. The UNITE platform can result in a number of downstream effects: CD4+ memory, cytokine production, and a potent antibody response. Rockville, Maryland, 20850, United States. ITI-2000 HPV+ Tumors. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. April 23, 2020 04:00 PM Eastern Daylight Time. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Missing the target in cancer therapy | Nature Cancer Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. ITI maintains its headquarters in Rockville, Maryland. Pays for all health and welfare insurance premiums 100%. ITI-2000 HPV+ Tumors. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. / Oct 13, 2015. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. This is the Immunomic Therapeutics company profile. 2017 Aug;47:85-92. The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . ImmunoMet Therapeutics - Crunchbase Company Profile & Funding Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. Immunomic, Colmmune partner on cancer immunotherapy - ScienceBoard.net Companies. Request a free trial. We provide a professional and challenging work environment . The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Harnessing the immune system to achieve deep and durable clinical responses in cancer. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. This day-long event includes an Advocacy Summit Liked by Priscilla Fussell Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Immunomic Therapeutics, Inc. Where the organization is headquartered (e.g. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Senior Scientist/Scientist II, Formulation Development. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Great people . Immunomic Therapeutics to present at the BIO CEO & Investor Conference William Hearl - President & CEO - Immunomic Therapeutics, Inc Report this profile . Coordinates: 245831.9N 1213154.0E. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. ITI-3000 Merkel Cell Carcinoma - pDNA. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Melody Carey We know that there are multiple aspects that inform our platform's success. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Vaccine technology developed at Johns Hopkins could lead to - Hub Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . This feature is in beta and may change with future updates. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Immunomic Therapeutics' nucleic acid vaccines have the . Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Contact Email info@immunomet.com. Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. You will receive a reply to confirm the receipt of your application. Amy Conrad Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Email credentials to careers@immunomix.com. Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Animal Health All. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. Our goal is to overcome the limitations of current immuno-oncology therapies by . The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. Active, Closed, Last funding round type (e.g. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. 2006 Aug 15;177(4):2265-75. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Eric Winzer - CFO - Immunomic Therapeutics, Inc. | LinkedIn 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Priscilla Fussell - Legal Counsel, Contracts & Intellectual Property 2020 Immunomic Therapeutics, Inc. All Rights Reserved. J Immunol Res. immunomic therapeutics crunchbase. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Founders Sungwuk Kim. CONTACT - MiNA Therapeutics | RNA Activation ITI-ID Candidate Multiple infectious diseases. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Pipeline - Immunomic Therapeutics Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. Working at Immunomic Therapeutics | Glassdoor In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Home - Immunomic Therapeutics In addition to our pipeline, we are also developing through collaborations with academic centers and biotechnology companies the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. The company is developing three small molecule products; its lead development program, IMU-838, a selective . Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC Curr Opin Immunol. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). ITI Company: Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Claim your Free Employer Profile. For more information, please visit www.immunomix.com. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. Immunomic Therapeutics Appoints Vice President, Cell Therapy As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. All content is posted anonymously by employees working at Immunomic Therapeutics. 301-968-3501 mkemp@immunomix.com You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Background. HLB also secured an option to make further investment into the company in the months ahead. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. 917-322-2571, Internet Explorer presents a security risk. 858-366-3243, Internet Explorer presents a security risk. What is health insurance like at Immunomic Therapeutics. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. These factors are currently under intense focus in the cancer immunotherapy landscape. Immunomic Therapeutics Announces the Appointment of Frances Harrison as